Valproic acid: A new narrative on its features and effects in traumatic brain injury

Glenn Wakam, Michael Kemp, Hasan Alam

Research output: Chapter in Book/Report/Conference proceedingChapter


Traumatic brain injury is a major cause of morbidity and mortality worldwide. Currently, the only treatment is supportive, with an emphasis on prevention of secondary injury. Our lab has over a decade of experience investigating histone deacetylase inhibitors (HDACIs), mainly valproic acid (VPA), as a treatment to improve survival and recovery after traumatic brain injury. In this chapter, we will review the cellular changes that occur after traumatic brain injury, the promising results of preclinical use of VPA in TBI, and the future of VPA use in traumatic brain injury.

Original languageEnglish (US)
Title of host publicationDiagnosis and Treatment of Traumatic Brain Injury
Subtitle of host publicationThe Neuroscience of Traumatic Brain Injury
PublisherElsevier Inc
Number of pages8
ISBN (Electronic)9780128233474
ISBN (Print)9780128233481
StatePublished - Jan 1 2022


  • Acetylation
  • Epigenetics
  • Histone deacetylase inhibitor
  • Neurodegeneration
  • Neurologic outcomes
  • Neuroplasticity
  • Pro-survival
  • Traumatic brain injury
  • Valproic acid

ASJC Scopus subject areas

  • General Medicine
  • General Neuroscience


Dive into the research topics of 'Valproic acid: A new narrative on its features and effects in traumatic brain injury'. Together they form a unique fingerprint.

Cite this